Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Non-Current Debt (2018 - 2019)

X4 Pharmaceuticals' Non-Current Debt history spans 2 years, with the latest figure at $22.2 million for Q2 2019.

  • For Q2 2019, Non-Current Debt rose 188.06% year-over-year to $22.2 million; the TTM value through Jun 2019 reached $22.2 million, up 188.06%, while the annual FY2018 figure was $8.3 million, N/A changed from the prior year.
  • Non-Current Debt reached $22.2 million in Q2 2019 per XFOR's latest filing, up from $8.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $22.2 million in Q2 2019 to a low of $7.7 million in Q2 2018.